|
Evening Primrose Oil
DESCRIPTION
Evening primrose oil (EPO) is high in the omega 6 fatty acid
gammalinolenic acid (GLA), which is readily converted in the
body to prostaglandin E1.
Evening primrose is a member
of the rosebay willow herb family. Its country name is derived
from the fact that its primrose yellow flowers open mainly
in the evening. The seeds from the flowers of the plant are
harvested and pressed to release the oil.
FUNCTIONS
GLA is an important intermediary
in the metabolic conversion of linoleic acid to prostaglandin
E1. Essentially that pathway goes as follows: Linoleic acid
(LA) is converted into gammalinolenic acid (GLA). GLA is then
converted into dihomo-gammalinolenic acid, which in turn is
converted into the final product, prostaglandin E1.
The normal diet is quite
sufficient in the essential fatty acid linoleic acid, but
the first step (LA to GLA) in its conversion to prostaglandin
E1 can be easily blocked. Among the known blocking agents
are: viruses, carcinogens, cholesterol, saturated fatty acids,
trans fatty acids, alcohol, insufficient insulin, excess dietary
alpha-linolenic acid (found in linseed and blackcurrant oils),
radiation, and the ageing process.
Dietary GLA can therefore
be extremely valuable since it skips these potential blockages.
Various nutrients are also
required for the production of prostaglandin. Zinc, Magnesium,
Biotin, and Vitamin
B6 are needed for the first step of the process, the conversion
of LA to GLA. Selenium, Vitamin
C , Niacin
, and Zinc
are needed for the subsequent conversion of GLA into prostaglandin
E1.
SUGGESTED INTAKES
For cyclic mastalgia (breast
pain related to menstrual cycles) or Eczema, 200-400 mg GLA
daily (2-4 g of evening primrose oil).
For diabetic neuropathy, 400-600 mg GLA daily (4 to 6 g of
evening primrose oil).
For rheumatoid Arthritis, 2000 to 3000 mg purified GLA. (Should
only be taken under the guidance of a medical professional).
Take with food. Signs of
improvement may take 6 months to develop.
SUPPLEMENTAL USES
Pre-menstrual syndrome
(PMS):
Evening primrose oil has been used with successful results
in women with PMS. It has been suggested that PMS may be linked
with a minor abnormality of essential fatty acid metabolism,
resulting in an inefficient conversion of fatty acids to prostaglandin
E1 (PGE1). Evidence shows that prostaglandin E1 (derived from
Essential
Fatty Acids ) is able to reduce the biological actions
of prolactin, an agent responsible for some PMS symptoms (1).
However, some other studies do not support these results (2).
In another study, evening
primrose oil was used with remarkable success. The symptoms
of swollen abdomen and breast discomfort were eradicated in
95% of the women, irritability in 80%, Depression in 74%,
swollen fingers and ankles in 79% and Anxiety in 53%. The
only two symptoms that persisted in more than half of the
women were tiredness and Headaches (3).
Evening primrose oil has
also been reported to substantially reduce the symptoms of
Benign Breast Disease (4).
Diabetes:
Evening primrose oil may be effective treatment for diabetic
neuropathy, which involves pain and/or numbness due to nerve
damage (5,6).
Heart and Cholesterol:
Evening primrose oil has been shown to lower high serum cholesterol
levels. Dietary supplementation with evening primrose oil
has also been shown to reduce platelet aggregation (blood
clotting) in those fed a normal or high fat diet (7,8).
Blood Pressure:
Studies have shown that GLA from evening primrose oil significantly
reduces blood pressure and may also inhibit the development
of Hypertension (9).
Skin Conditions:
Evening primrose oil has been used successfully in patients
with atopic Eczema. A double blind cross-over study was used
with adults taking either 4, 8 or 12 x 500mg capsules daily
and children taking 4 or 8 x 500mg capsules daily. Results
indicated that evening primrose oil brought significant clinical
improvement to Dermatitis, especially at the higher intakes
(10).
Multiple sclerosis:
Evening primrose oil is routinely used by Multiple sclerosis
sufferers (11). The unusual pattern of fatty acids found in
the brain of MS sufferers may return to normal within a few
months of taking EPO.
Rheumatoid Arthritis:
49 patients, all long-standing sufferers of Arthritis and
taking non-steroidal anti-inflammatory (NSAID) drugs, were
given either evening primrose oil or evening primrose oil
plus Fish Oil
s. 60% of the patients were able to withdraw completely from
NSAID treatment, and another 25% were able to cut their NSAID
dosage in half. Evening primrose oil with Fish
Oils was slightly more effective than EPO alone (12).
SAFETY
Evening primrose oil can
be used without harm at levels of up to 5-6g daily.
INTERACTIONS AND CONTRA-INDICATIONS
ALA:
Alpha linolenic acid (found in linseed and blackcurrant oil)
has a blocking effect on the conversion of GLA/linoleic acid
into prostaglandins.
Epilepsy:
Evening primrose oil should be avoided by epileptics as it
may exacerbate a certain type of temporal lobe epilepsy.
Schizophrenia:
Also, evening primrose oil is best not taken with drugs for
Schizophrenia.
Miscellaneous:
Occasionally, evening primrose oil may cause nausea, Headaches
or Skin eruptions when first taken. Symptoms can be lessened
by taking with a meal.
REFERENCES
1. "Primrose
oil in the treatment of Pre-menstrual syndrome", B Larsson
& S Fianu, Dept. Obstetrics and Gynaecology, Hudding University
Hospital, Sweden, 1986.
2. J Obstetrics and Gynaecology, 1993,81;1:93-98.
3. Current Therapeutic Research, 1989, 46;1:58-63.
4. "Handbook of Dietary Supplements", Pamela Mason,
Blackwell Science, 1995.
5. Keen H, Payan J, Allawi J, et al. Treatment of diabetic
neuropathy with gamma-linolenic acid. The Gamma-Linolenic
Acid Multicenter Trial Group. Diabet Care 16: 8-15, 1993.
6. Jamal GA and Carmichael H. The effect of gamma-linolenic
acid on human diabetic peripheral neuropathy: a double-blind
placebo-controlled trial. Diabet Med 7: 319-323, 1990.
7. Lipids, 1997,32;10:1069-1074.
8. Annales de la Nutrition et de l’Alimentation, 1980,34;2:277-290.
9. Prostaglandins Leukot Essent Fatty Acids, 1993,49;4:809-814.
10. The J Int Medical Res, 1994;22:24-32.
11. The Lancet, 1997,350;9092:1685.
12. Annals of the Rheumatic Diseases, 1988,47:96-104.
|